Eli Lilly has confirmed that one person has received its investigational triple-agonist weight-loss drug retatrutide through the company’s compassionate use program. Multiple news outlets, including Mother Jones and STAT News, have reported that the recipient is former U.S. President Donald Trump, raising significant questions about how unapproved therapies are allocated before regulatory approval and what the episode reveals about equity in drug access.
The Compassionate Use Framework
Compassionate use — formally known as expanded access — allows patients with serious or life-threatening conditions to receive investigational drugs outside of clinical trials when no comparable therapeutic alternatives exist. In the United States, the FDA oversees this process, though the decision to grant access ultimately rests with the drug manufacturer. Companies are not required to provide expanded access, and they face no legal obligation to create or publicize their expanded access policies.
Eli Lilly, like many large pharmaceutical companies, maintains an internal review process for compassionate use requests. The company evaluates factors including the patient’s medical need, the stage of clinical development, available safety data, and manufacturing capacity. A spokesperson confirmed to STAT News that the company has “offered retatrutide to a single person via compassionate use,” but declined to comment on the patient’s identity, citing privacy considerations.
The revelation that a former president — who has long downplayed the health risks of obesity — may have received privileged access to an unapproved drug has drawn scrutiny from patient advocacy groups and health equity researchers. Critics argue that the episode underscores fundamental inequities in how experimental therapies are distributed.
“We have a system where people with means and connections can access cutting-edge treatments that are completely unavailable to the average person suffering from the same condition,” one bioethicist told Mother Jones. “That’s not a compassionate use program — that’s a concierge medicine model for the powerful.”
What Makes This Case Unusual
Several factors distinguish this compassionate use case from the norm. Retatrutide is still in Phase 3 clinical trials, and while the TRIUMPH-1 results presented at the American Diabetes Association’s 86th Scientific Sessions demonstrated unprecedented weight loss — averaging up to 24.2% at the highest dose over 72 weeks — the drug has not yet been submitted for FDA approval. Lilly has indicated it plans to file for regulatory approval in late 2026, with a potential commercial launch in 2027.
Providing expanded access at this stage, before a New Drug Application has been filed, is atypical. Most compassionate use programs are initiated after Phase 3 data is complete and the approval process is underway, giving regulators and the company a fuller picture of the drug’s risk-benefit profile.
Furthermore, manufacturing capacity for retatrutide is constrained. Lilly is investing billions in new production facilities — including a $5.3 billion expansion in Germany — but current supply is allocated primarily to ongoing clinical trials. Diverting doses to a single individual, even one dose per week for a single patient, raises logistical questions about how the company prioritizes its limited supply.
Political Context
Trump’s reported use of retatrutide carries significant political dimensions. During his 2024 presidential campaign, Trump faced public discussion about his weight and health. Medical experts noted that an effective weight-loss treatment could have meaningful health implications for someone with his publicly reported body mass index and age.
The Trump administration’s healthcare policy positions — including efforts to roll back the Affordable Care Act’s protections for pre-existing conditions and proposals to limit Medicare’s ability to negotiate drug prices — stand in tension with the emerging reality that GLP-1 receptor agonists and multi-agonist drugs like retatrutide could become among the most prescribed medications in the country. Medicare’s decision on whether to cover weight-loss drugs remains one of the most consequential healthcare policy questions of the decade.
Canadian Context: The Special Access Programme
For Canadians, the Trump compassionate use case highlights important differences — and similarities — in how unapproved drugs are accessed north of the border.
Health Canada operates a Special Access Programme (SAP) that allows healthcare practitioners to request access to drugs that are not yet authorized for sale in Canada. Unlike the U.S. system, where the manufacturer holds primary decision-making power, Canada’s SAP involves Health Canada as an intermediary. A physician must submit a request detailing the patient’s medical condition and why authorized therapies are unsuitable. Health Canada reviews the application and, if approved, authorizes the manufacturer to release the drug.
Key differences from the U.S. expanded access framework:
- Government oversight: Health Canada is an active participant in the approval process rather than relying solely on manufacturer discretion.
- Transparency: SAP authorizations are tracked and reported in aggregate, though individual patient identities remain confidential.
- Cost: Patients may need to cover the cost of the drug themselves, as provincial formularies and private insurers typically do not cover unapproved therapies.
As retatrutide advances toward regulatory submission, Canadian patients and physicians will be watching closely. Eli Lilly Canada has a presence in the country, and the company has engaged with Health Canada on prior drug approvals. Whether a Canadian expanded access pathway for retatrutide will be available before formal authorization remains unclear.
The Bigger Picture: Equity in Obesity Treatment
The compassionate use controversy arrives at a moment when policymakers, insurers, and patient advocates are grappling with fundamental questions about obesity treatment access. The TRIUMPH-1 results confirmed that retatrutide can produce weight loss approaching the levels seen with bariatric surgery, potentially reshaping treatment paradigms for a condition affecting over 40% of American adults.
But a drug that works does society little good if only the powerful and well-connected can obtain it. The retatrutide story is unfolding against a backdrop of widespread GLP-1 shortages, formulary restrictions that limit coverage, and list prices that put these drugs out of reach for uninsured and underinsured patients.
If a former president can secure access to an unapproved drug through a process that remains opaque to ordinary patients, the compassionate use system may need reform. As one advocate succinctly put it: “Compassionate use should be about medical need, not political power.”